Siemens Healthineers stock enters a two-track restructuring

Published on 11/07/2026 at 12:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Siemens Healthineers stock enters a two-track restructuring as diagnostics moves toward separation. The unit will use the Olyrian Diagnostics name.

Strategic changes reshape the group

Siemens Healthineers is carving out its in vitro diagnostics business under the Olyrian Diagnostics name.
The diagnostics unit is expected to remain part of the group during the transition toward a standalone organization.
A JPMorgan roadshow is scheduled in London for November 9.

Siemens Healthineers, DE000SHL1006, Illustration mit AI erstellt.

Siemens Healthineers said on Thursday, November 5, that it had begun carving out its in vitro diagnostics business and would rebrand the unit as Olyrian Diagnostics. Reuters reported that the separation is expected to be completed by mid-2028.

Diagnostics moves toward separation

Olyrian Diagnostics will remain part of Siemens Healthineers during the transition. The business performs more than 16 billion diagnostic tests annually and represents about 17 percent of group revenue and roughly 20 percent of its workforce, according to Reuters.

The separate name is intended to position the diagnostics operation as a standalone business while the carve-out progresses. Siemens Healthineers is also preparing to rename itself Healthineers.

Investor calendar remains active

The company’s investor relations calendar lists the fiscal 2026 fourth-quarter results released on November 5 and a JPMorgan roadshow in London on November 9.

The real-time quote of Siemens Healthineers stock was 44.51 euros on Lang & Schwarz at 12:36 CET on Saturday, November 7, 2026.